Affiliation:
1. Far-Eastern State Medical University, Ministry of Health of the Russian Federation
Abstract
The aim of the study is to evaluate the excreted uric acid fraction in patients with oxalate nephropathy in the early stages of chronic kidney disease with gonarthritis under non-steroidal anti-inflammatory drug therapy.
Materials and Methods. An open, comparative, randomized study included 192 women, aged 51.4±2.3, with oxalate nephropathy and primary gonarthritis. The glomerular filtration rate was >60 ml/min, BMI – 23.4±1.8. The first group of patients was taking Diclofenac Sodium (4500 mg/month), the second group – Celecoxib (6000 mg/month), the third group – Nimesulide (6000 mg/month), the fourth group – Diacerein (6000 mg/2 months). The control group for each drug consisted of patients with gonarthritis, but without nephropathy and hyperuricemia. The patients of the control groups were treated similarly. The excreted fraction of uric acid in the subjects was assessed on Day 15, Day 30, and Day 60 according to generally accepted methods.
Results. A decrease in the excreted fraction of uric acid, hyperuricemia, and a decrease in the glomerular filtration rate were observed in patients taking Diclofenac. After one-month Diclofenac withdrawl, the parameters did not return to their original levels. Celecoxib and Nimesulide had margical effect on the changes of the excreted uric acid fraction and a decrease in glomerular filtration rate. A month after their withdrawl, the parameters returned to their original levels. Diacerein had no effect on the renal transport of uric acid. No significant changes were noted in the control.
Publisher
Ulyanovsk State University
Reference21 articles.
1. Ratsional'noe ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [Efficient use of non-steroidal anti-inflammatory drugs. Clinical guidelines]. Nauchno-prakticheskaya revmatologiya. 2018; 56 (pril. 1): 1–29 (in Russian).
2. Alekseeva L.I., Taskina E.A., Kashevarova N.G. Osteoartrit: epidemiologiya, klassifikatsiya, faktory riska i progressirovaniya, klinika, diagnostika, lechenie [Osteoarthritis: Epidemiology, classification, risk factors, progression, clinical picture, diagnosis, and treatment]. Sovremennaya revmatologiya. 2019; 13 (2): 9–21 (in Russian).
3. Alekseeva L.I., Kashevarova N.G., Taskina E.A., Sharapova E.P., Anikin S.G., Korotkova T.A., Strebkova E.A. Effektivnost' i bezopasnost' diatsereina u patsientov s osteoartritom kolennykh sustavov [Efficacy and safety of Diacerein in patients with knee osteoarthritis]. Sovremennaya revmatologiya. 2017; 11 (3): 1–8 (in Russian).
4. Naumov A.V., Khovasova N.O. Rekomendovannaya terapiya osteoartrita: novye resheniya starykh zadach [Osteoarthritis treatment: New solutions to old problems]. RMZh. 2016; 3: 1–4 (in Russian).
5. Karateev A.E., Alekseeva L.I. Otsenka perenosimosti diatsereina v real'noy klinicheskoy praktike. Rezul'taty issledovaniya ROKADA (Retrospektivnaya otsenka klinicheskikh aspektov primeneniya Diafleksa pri osteoartroze) [Evaluation of Diacerein acceptability in real clinical practice. Results of the clinical study (Retrospective evaluation of clinical aspects of Diaflex therapy in osteoarthritis)]. Nauchno-prakticheskaya revmatologiya. 2015; 53 (2): 169–174 (in Russian).